dc.contributor.author | Schoenen, Jean | |
dc.contributor.author | Ertas, Mustafa | |
dc.contributor.author | Del Rio, Margarita Sdnchez | |
dc.contributor.author | Schwalen, Susanne | |
dc.contributor.author | van Oene, Joop | |
dc.contributor.author | Diener, Hans-Christoph | |
dc.contributor.author | Agosti, Reto | |
dc.contributor.author | Allais, Gianni | |
dc.contributor.author | Bergmans, Paul | |
dc.contributor.author | Bussone, Gennaro | |
dc.contributor.author | Davies, Brendan | |
dc.contributor.author | Lanteri-Minet, Michel | |
dc.contributor.author | Reuter, Uwe | |
dc.date.accessioned | 2021-03-04T07:50:39Z | |
dc.date.available | 2021-03-04T07:50:39Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | Diener H., Agosti R., Allais G., Bergmans P., Bussone G., Davies B., Ertas M., Lanteri-Minet M., Reuter U., Del Rio M. S. , et al., "Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial", LANCET NEUROLOGY, cilt.6, sa.12, ss.1054-1062, 2007 | |
dc.identifier.issn | 1474-4422 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_60323863-1b17-4eb7-8378-1f0d08c72e56 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/67151 | |
dc.identifier.uri | https://doi.org/10.1016/s1474-4422(07)70272-7 | |
dc.description.abstract | Background Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of topiramate after a treatment period of 6 months. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Nöroloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | KLİNİK NEUROLOJİ | |
dc.title | Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial | |
dc.type | Makale | |
dc.relation.journal | LANCET NEUROLOGY | |
dc.contributor.department | University of Duisburg Essen , , | |
dc.identifier.volume | 6 | |
dc.identifier.issue | 12 | |
dc.identifier.startpage | 1054 | |
dc.identifier.endpage | 1062 | |
dc.contributor.firstauthorID | 185565 | |